These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35397092)

  • 21. Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial.
    Helliwell PS; Deodhar A; Gottlieb AB; Boehncke WH; Xu XL; Xu S; Wang Y; Hsia EC; Gladman DD; Ritchlin CT
    Arthritis Care Res (Hoboken); 2020 Nov; 72(11):1579-1588. PubMed ID: 31421033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
    Nash P; Kirkham B; Okada M; Rahman P; Combe B; Burmester GR; Adams DH; Kerr L; Lee C; Shuler CL; Genovese M;
    Lancet; 2017 Jun; 389(10086):2317-2327. PubMed ID: 28551073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity.
    Coates LC; Orbai AM; Morita A; Benichou O; Kerr L; Adams DH; Shuler CL; Birt J; Helliwell PS
    BMC Rheumatol; 2018; 2():24. PubMed ID: 30886974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies.
    Combe B; Tsai TF; Huffstutter JE; Sprabery AT; Lin CY; Park SY; Kronbergs A; Hufford MM; Nash P
    Arthritis Res Ther; 2021 Jan; 23(1):41. PubMed ID: 33499913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials.
    Mease P; Kavanaugh A; Gladman D; FitzGerald O; Soriano ER; Nash P; Feng D; Lertratanakul A; Douglas K; Lippe R; Gossec L
    Rheumatol Ther; 2022 Aug; 9(4):1181-1191. PubMed ID: 35606663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H.
    Kristensen LE; Okada M; Tillett W; Leage SL; El Baou C; Sapin C; Bradley AJ; Meszaros G; Dutz JP; de Vlam K
    Rheumatol Ther; 2022 Feb; 9(1):109-125. PubMed ID: 34709605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Threshold of Meaning for Work Disability Improvement in Psoriatic Arthritis Measured by the Work Productivity and Activity Impairment Questionnaire.
    Tillett W; Lin CY; Zbrozek A; Sprabery AT; Birt J
    Rheumatol Ther; 2019 Sep; 6(3):379-391. PubMed ID: 31154634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Residual Disease Activity and Associated Factors in Psoriatic Arthritis.
    Lubrano E; Scriffignano S; Perrotta FM
    J Rheumatol; 2020 Oct; 47(10):1490-1495. PubMed ID: 31676704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries.
    Gorlier C; Orbai AM; Puyraimond-Zemmour D; Coates LC; Kiltz U; Leung YY; Palominos P; Cañete JD; Scrivo R; Balanescu A; Dernis E; Tälli S; Ruyssen-Witrand A; Soubrier M; Aydin SZ; Eder L; Gaydukova I; Lubrano E; Kalyoncu U; Richette P; Husni ME; de Wit M; Smolen JS; Gossec L
    Ann Rheum Dis; 2019 Feb; 78(2):201-208. PubMed ID: 30442648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort.
    van Mens LJJ; van de Sande MGH; van Kuijk AWR; Baeten D; Coates LC
    Ann Rheum Dis; 2018 Feb; 77(2):251-257. PubMed ID: 29080861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors.
    Kirkham B; Sesin C; Gellett AM; Sprabery AT; Lin CY; Turkiewicz A
    Rheumatology (Oxford); 2021 Sep; 60(9):4367-4372. PubMed ID: 33479721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1.
    Coates LC; Kishimoto M; Gottlieb A; Shuler CL; Lin CY; Lee CH; Mease PJ
    RMD Open; 2017; 3(2):e000567. PubMed ID: 29299340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
    Kirkham BW; Egeberg A; Behrens F; Pinter A; Merola JF; Holzkämper T; Gallo G; Ng KJ; Bolce R; Schuster C; Nash P; Puig L
    Rheumatol Ther; 2023 Oct; 10(5):1127-1146. PubMed ID: 37400681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).
    Gottlieb AB; Strand V; Kishimoto M; Mease P; Thaçi D; Birt J; Lee CH; Shuler CL; Lin CY; Gladman DD
    Rheumatology (Oxford); 2018 Oct; 57(10):1777-1788. PubMed ID: 29945203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
    Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ
    Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study.
    Coates LC; Mease PJ; Gladman DD; Navarra S; Bao W; Gaillez C
    RMD Open; 2023 Apr; 9(2):. PubMed ID: 37094983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis.
    Ogdie A; Gladman DD; Coates LC; Pournara E; Parikh B; Mease PJ
    Rheumatol Ther; 2023 Aug; 10(4):849-860. PubMed ID: 37148474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis.
    Hagège B; Tan E; Gayraud M; Fautrel B; Gossec L; Mitrovic S
    Rheumatology (Oxford); 2020 Aug; 59(8):1818-1825. PubMed ID: 32118267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis.
    Combe B; Rahman P; Kameda H; Cañete JD; Gallo G; Agada N; Xu W; Genovese MC
    Arthritis Res Ther; 2020 Jan; 22(1):14. PubMed ID: 31964419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).
    Chandran V; van der Heijde D; Fleischmann RM; Lespessailles E; Helliwell PS; Kameda H; Burgos-Vargas R; Erickson JS; Rathmann SS; Sprabery AT; Birt JA; Shuler CL; Gallo G
    Rheumatology (Oxford); 2020 Oct; 59(10):2774-2784. PubMed ID: 32031665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.